Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation

被引:10
作者
Yoon, Jae-Ho [1 ]
Lee, Seok [1 ]
Kim, Hee-Je [1 ]
Lee, Jong-Wook [1 ]
Min, Woo-Sung [1 ]
Chung, Byung Ha [2 ]
Yang, Chul Woo [2 ]
Kim, Yong-Soo [2 ]
Kim, Ji-Il [3 ]
Moon, In Sung [3 ]
Oh, Eun Ji [4 ]
Park, Gyeong-Sin [5 ]
Cho, Seok-Goo [1 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Blood & Marrow Transplantat Ctr, Dept Hematol, Seoul 137701, South Korea
[2] Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Nephrol, Seoul 137701, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Surg, Seoul 137701, South Korea
[4] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Lab Med, Seoul 137701, South Korea
[5] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Pathol, Seoul 137701, South Korea
关键词
hematopoietic stem cell transplantation; kidney transplantation; post-transplant lymphoproliferative disorder; prognosis; SOLID-ORGAN TRANSPLANTATION; PROGNOSTIC-FACTORS; RITUXIMAB; RECIPIENTS; LYMPHOMAS; PTLD; IMMUNOSUPPRESSION; SURVIVAL; DISEASE;
D O I
10.1111/tri.12328
中图分类号
R61 [外科手术学];
学科分类号
摘要
Post-transplant lymphoproliferative disorder (PTLD) is a major complication caused by immune-suppression after transplantation. Survival outcome is known to be poor and the characteristics are not fully understood because of its rare incidence. This single center retrospective study enrolled 41 adult PTLD patients after kidney-transplantation (KT, n=28) and hematopoietic stem cell transplantation (HSCT, n=13) from 1992 to 2012. We compared the characteristics and estimated the survival outcomes according to several factors [age-adjusted-IPI (aaIPI), pathologic subtype, viral status, extranodal manifestation] and added some significant parameters to aaIPI scoring system. Post-HSCT-PTLD patients were younger and showed earlier onset, and viral status was more frequently identified. Ten-year OS of the entire group was 44% but the 10-year OS was not significantly different between post-KT-PTLD and post-HSCT-PTLD (39% vs. 56%, P=0.860). The time onset of PTLD and viral statuses were not meaningful, however, aaIPI, age>50, extranodal manifestation and monomorphic subtype were predictive for OS. We used those factors for PTLD-specific scoring which showed intermediate-risk (HR=7.1, P=0.019) and high-risk (HR=16.5, P=0.001) presented worse OS compared to low-risk subgroup. Although the treatment strategies were heterogenous, this study showed comprehensive PTLD data between KT versus HSCT, and our PTLD-specific scoring might be validated by another larger studies.
引用
收藏
页码:721 / 732
页数:12
相关论文
共 50 条
  • [31] Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
    Liu, Li
    Liu, Qifa
    Feng, Sizhou
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [32] Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
    Zhu, Cheng-ying
    Zhao, Sha-sha
    Wang, Xiao-kai
    Wang, Li
    Wang, Fei-yan
    Fang, Shu
    Liu, Zhan-xiang
    Guan, Li-xun
    Liu, Yu-chen
    Ding, Yi
    Dou, Li-ping
    Wang, Li-li
    Gao, Chun-ji
    ANNALS OF TRANSPLANTATION, 2019, 24 : 175 - 184
  • [33] Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
    Uhlin, Michael
    Wikell, Helena
    Sundin, Mikael
    Blennow, Ola
    Maeurer, Markus
    Ringden, Olle
    Winiarski, Jacek
    Ljungman, Per
    Remberger, Mats
    Mattsson, Jonas
    HAEMATOLOGICA, 2014, 99 (02) : 346 - 352
  • [34] Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score
    Caillard, Sophie
    Porcher, Raphael
    Provot, Francois
    Dantal, Jacques
    Choquet, Sylvain
    Durrbach, Antoine
    Morelon, Emmanuel
    Moal, Valerie
    Janbon, Benedicte
    Alamartine, Eric
    Noble, Claire Pouteil
    Morel, Delphine
    Kamar, Nassim
    Buchler, Matthias
    Mamzer, Marie France
    Peraldi, Marie Noelle
    Hiesse, Christian
    Renoult, Edith
    Toupance, Olivier
    Rerolle, Jean Philippe
    Delmas, Sylvie
    Lang, Philippe
    Lebranchu, Yvon
    Heng, Anne Elisabeth
    Rebibou, Jean Michel
    Mousson, Christiane
    Glotz, Denis
    Rivalan, Joseph
    Thierry, Antoine
    Etienne, Isabelle
    Moal, Marie Christine
    Albano, Laetitia
    Subra, Jean Francois
    Ouali, Nacera
    Westeel, Pierre Francois
    Delahousse, Michel
    Genin, Robert
    de Ligny, Bruno Hurault
    Moulin, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) : 1302 - 1309
  • [35] Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation
    Kinzel, Megan
    Dowhan, Michelle
    Kalra, Amit
    Williamson, Tyler S.
    Dabas, Rosy
    Jamani, Kareem
    Chaudhry, Ahsan
    Shafey, Mona
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Daly, Andrew
    Dharmani-Khan, Poonam
    Khan, Faisal
    Storek, Jan
    TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (01): : 53.e1 - 53.e10
  • [36] Comparison of Post-Transplantation Lymphoproliferative Disorder Risk and Prognostic Factors between Kidney and Liver Transplant Recipients
    Mucha, Krzysztof
    Staros, Rafal
    Foroncewicz, Bartosz
    Ziarkiewicz-Wroblewska, Bogna
    Kosieradzki, Maciej
    Nazarewski, Slawomir
    Naumnik, Beata
    Raszeja-Wyszomirska, Joanna
    Zieniewicz, Krzysztof
    Paczek, Leszek
    CANCERS, 2022, 14 (08)
  • [37] Effect of Irradiation on Incidence of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation in Miniature Swine
    Matar, Abraham J.
    Patil, Aarti R.
    Al-Musa, Ahmad
    Hanekamp, Isabel
    Sachs, David H.
    Huang, Christene A.
    Duran-Struuck, Raimon
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (10) : 1732 - 1738
  • [38] Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children
    Chiou, Fang Kuan
    Beath, Sue V.
    Wilkie, Gwen M.
    Vickers, Mark A.
    Morland, Bruce
    Gupte, Girish L.
    PEDIATRIC TRANSPLANTATION, 2018, 22 (02)
  • [39] Post-transplant Lymphoproliferative Disorders after Solid Organ Transplantation in Children
    Colita, A.
    Colita, A.
    Moise, L.
    Arion, C.
    Popescu, I.
    CHIRURGIA, 2012, 107 (04) : 431 - 437
  • [40] Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation
    Dharnidharka, VR
    Stevens, G
    PEDIATRIC TRANSPLANTATION, 2005, 9 (05) : 622 - 626